SCHEMBL25544767

SCHEMBL25544767

COC(=O)C12CC(Nc3nc4cc(C)ccc4c(-c4ccc(F)cc4)c3C3CCOCC3)(C1)C2

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.36
CTNNB1 P35222 4/20 0.34
TCF7L2 Q9NQB0 4/20 0.34
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
ABL1 P00519 3/20 0.32
MOK Q9UQ07 1/20 0.32
CFTR P13569 1/20 0.32
SAE1 Q9UBE0 1/20 0.31
UBA2 Q9UBT2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPK10 P53779 1/20 0.31
KMT2A Q03164 1/20 0.31
SOS1 Q07889 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HDAC3 O15379 1/20 0.30
GRM5 P41594 1/20 0.30
PDE5A O76074 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544781 0.92 HDAC1 (0.33) HDAC1HDAC2ABL1SMN1; SMN2PDE5A
SCHEMBL25189338 0.85 PARP14 (0.39)
SCHEMBL23887789 0.82 HDAC1 (0.35) GRM2HDAC1HDAC2HDAC3
SCHEMBL25544311 0.76 GRM2 (0.41) GRM2CTNNB1TCF7L2MOKSAE1
SCHEMBL25544319 0.74 GRM2 (0.38) GRM2CTNNB1TCF7L2MOKMEN1
SCHEMBL25544757 0.74 PDE10A (0.39) GRM2CTNNB1TCF7L2MEN1KMT2A
SCHEMBL25544789 0.73 CTNNB1 (0.40) GRM2CTNNB1TCF7L2MOK
SCHEMBL23896399 0.70 ESR1 (0.33) GRM2HDAC1HDAC2PDE5A
SCHEMBL23896107 0.70 PDE10A (0.36) HDAC1HDAC2PDE5A
SCHEMBL23895810 0.70 PDE10A (0.36) HDAC1HDAC2PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 GRM2 4755/4885CTNNB1 1574/4885TCF7L2 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.